BioSpace News Archive

New York City, NY: April 08, 2020 – Published: The demand in the global electrosurgical products market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications. On the other hand, the absence of a predefined regulatory f

New York City, NY: April 08, 2020 – Published: The demand in the global eosinophilic esophagitis drug market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications. On the other hand, the absence of a predefined regulat

The demand in the global extracorporeal blood treatment market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications.

New York City, NY: April 08, 2020 – Published: The demand in the global fetal heart monitor market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications. On the other hand, the absence of a predefined regulatory framew

The demand in the global fragment-based drug discovery market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications.

The demand in the global general surgical devices market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications.

New York City, NY: April 08, 2020 – Published: The demand in the global gastrointestinal stents market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications. On the other hand, the absence of a predefined regulatory fr

The demand in the global genomic biomarker market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications.

LabCorp, UC San Diego and the National Institute of Allergy and Infectious Diseases are among the organizations utilizing PacBio’s highly accurate long-read sequencing technology to study SARS-CoV-2 and the related immune response to COVID-19 MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it is working with commercial, a

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced its financial results for the fourth quarter and year ended December 31, 2019.